Liver transplantation for hepatocellular carcinoma on cirrhosis:Strategies to avoid tumor recurrence

作     者：Marco Vivarelli Andrea Risaliti 

作者机构：Department of Surgery and TransplantationUniversity of BolognaS Orsola Hospital Department of Hepatobiliopancreatic and Transplantation SurgeryPolytechnic University of MarcheOspedali Riuniti 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2011年第17卷第43期

页      面：4741-4746页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Chemotherapy Hepatocellular carcinoma Immunosuppression Liver transplantation Tumor recurrence 

摘      要：Hepatocellular carcinoma(HCC) is one of the most frequent neoplasms worldwide and in most cases it is associated with chronic liver *** transplantation(LT) is potentially the optimal treatment for those patients with HCC who have a poor functional hepatic reserve due to their underlying chronic liver ***,due to the limited availability of donors,only those patients whose oncologic profile is favorable can be considered for *** the careful selection of candidates based on strict rules,10 to 20%of liver transplant recipients who have HCC in the native cirrhotic liver develop tumor recurrence after *** selection criteria presently employed to minimize the risk of recurrence are based on gross tumor characteristics defined by imaging techniques;unfortunately,the accuracy of imaging is far from being ***,microscopic tumor features that are strictly linked with prognosis can not be assessed prior to ***-transplantation tumor downstaging may allow transplantation in patients initially outside the selection criteria and seems to improve the prognosis;it also provides information on tumor *** peculiarity of the transplantation setting,when this is compared with other modalities of treatment,is the need for pharmacological immunosuppression:this is based on drugs that have been demonstrated to increase the risk of tumor *** HCC is an aggressive malignancy,immunosuppression has to be handled carefully in patients who have HCC at the time of transplantation and new categories of immunosuppressive agents should be *** chemotherapy following transplantation has failed to show any significant *** aim of the present study is to review the possible strategies to avoid recurrence of HCC after liver transplantation based on the current clinical evidence and the more recent developments and to discuss possible future directions.